Publications in collaboration with researchers from Ludwig Maximilian University of Munich (11)

2022

  1. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

    npj Precision Oncology, Vol. 6, Núm. 1

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121

  2. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

    Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180

2019

  1. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study

    Journal of Clinical Oncology

2018

  1. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial

    Annals of Oncology, Vol. 29, Núm. 4, pp. 888-894

  2. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Palbociclib and letrozole in advanced breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177